Transcervical, intrauterine ultrasound-guided radiofrequency ablation of uterine fibroids with the VizAblate® System: three- and six-month endpoint results from the FAST-EU study

Table 5 Improvement in patient reported outcomes at 6 months

	Baseline	6 Months	% Improvement from baseline	P value^a
MP	48	43	43	<0.0001
	418 ± 251	146 ± 144	60.8 ± 38.2 %
	361	98	70.8 %
	(119–1582)	(0–786)	(−73.1–100 %)
UFS-QOL SSS	48	44	44	<0.0001
	62.1 ± 16.8	23.5 ± 17.8	59.7 ± 30.4 %
	60.9	18.8	66.7 %
	(28.1–100)	(0.0–78.1)	(−22.2–100 %)
UFS-QOL HRQOL	47	43	43	<0.0001
	34.5 ± 18.7	82.5 ± 17.8	263 ± 468 %
	30.2	86.2	126.0 %
	(0.0–73.3)	(12.9–100)	(−28.6–2800 %)

Data are number of subjects; mean ± standard deviation; median; (range)
MP menstrual pictogram, UFS-QOL SSS uterine fibroid symptom and health-related quality of life symptom severity score subscale, UFS-QOL HRQOL uterine fibroid symptom and health-related quality of life health-related quality of life subscale
^aWilcoxon signed-rank test, null hypothesis of no change